{"protocolSection": {"identificationModule": {"nctId": "NCT02630706", "orgStudyIdInfo": {"id": "8835-012"}, "secondaryIdInfos": [{"id": "B1521045", "type": "OTHER", "domain": "Pfizer Protocol Number"}, {"id": "MK-8835-012", "type": "OTHER", "domain": "Merck Protocol Number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)", "officialTitle": "A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control on Metformin Monotherapy (VERTIS-ASIA)"}, "statusModule": {"statusVerifiedDate": "2018-11", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12-16", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-12-27", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-12-27", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-12-11", "studyFirstSubmitQcDate": "2015-12-11", "studyFirstPostDateStruct": {"date": "2015-12-15", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-11-13", "resultsFirstSubmitQcDate": "2018-11-13", "resultsFirstPostDateStruct": {"date": "2018-12-07", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-11-13", "lastUpdatePostDateStruct": {"date": "2018-12-07", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "collaborators": [{"name": "Pfizer", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the mean reduction from baseline in HbA1C for 15 mg and 5 mg ertugliflozin (tested sequentially) is greater than for placebo.", "detailedDescription": "This study includes a 1-week screening period, an 8-week (or greater) antihyperglycemic agent (AHA) wash-off and/or metformin dose stable period (as necessary), a 2-week single-blind placebo run-in period, a 26-week double-blind treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "maskingDescription": "Sponsor was masked.", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 506, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Ertugliflozin 5 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.", "interventionNames": ["Drug: Ertugliflozin 5 mg", "Drug: Placebo matching ertugliflozin", "Drug: Metformin", "Drug: Glimepiride"]}, {"label": "Ertugliflozin 15 mg", "type": "EXPERIMENTAL", "description": "Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.", "interventionNames": ["Drug: Ertugliflozin 15 mg", "Drug: Metformin", "Drug: Glimepiride"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.", "interventionNames": ["Drug: Placebo matching ertugliflozin", "Drug: Metformin", "Drug: Glimepiride"]}], "interventions": [{"type": "DRUG", "name": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral tablet taken once daily", "armGroupLabels": ["Ertugliflozin 5 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily", "armGroupLabels": ["Ertugliflozin 15 mg"], "otherNames": ["MK-8835", "PF-04971729"]}, {"type": "DRUG", "name": "Placebo matching ertugliflozin", "description": "Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily", "armGroupLabels": ["Ertugliflozin 5 mg", "Placebo"]}, {"type": "DRUG", "name": "Metformin", "description": "Participants are to remain on their stable doses of metformin (oral, \\>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \\<1500 at screening are up-titrated to \\>= 1500 daily.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg", "Placebo"]}, {"type": "DRUG", "name": "Glimepiride", "description": "Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.", "armGroupLabels": ["Ertugliflozin 15 mg", "Ertugliflozin 5 mg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to 28 weeks"}, {"measure": "Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to 28 weeks"}, {"measure": "Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to 26 weeks"}, {"measure": "Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to 26 weeks"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Baseline and Week 26"}, {"measure": "Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "timeFrame": "Week 26"}, {"measure": "Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "timeFrame": "Week 26"}, {"measure": "Time to Glycemic Rescue Therapy", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "timeFrame": "Up to 183 days"}, {"measure": "Time to Glycemic Rescue Therapy (China Subpopulation)", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "timeFrame": "Up to 149 days"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 6: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 12: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 12: 60 min. Post-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 18: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 18: 60 min. Post-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 26: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 6: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 12: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 12: 60 min. Post-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 18: Pre-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 18: 60 min. Post-Dose"}, {"measure": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "timeFrame": "Week 26: Pre-Dose"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Asian participants \u226518 years of age at the time of initial Screening.\n* Type 2 diabetes mellitus as per American Diabetes Association guidelines.\n* Metformin monotherapy (\u22651500 mg/day) with an initial Screening A1C of 7.0-10.5% (53-91 mmol/mol) OR metformin monotherapy (\\<1500 mg/day) with an initial Screening A1C of 7.5-11.0% (58-97 mmol/mol) OR dual combination therapy with metformin + sulfonylurea, dipeptidyl peptidase-4 (DDP-4) inhibitor, meglitinide, or alpha-glucosidase inhibitor with an initial Screening A1C of 6.5-9.5% (48-80 mmol/mol).\n* Body mass index (BMI) \u226518.0 kg/m\\^2.\n* Male or female not of reproductive potential.\n* Female of reproductive potential who agrees to remain abstinent from heterosexual activity or to use 2 acceptable combinations of contraception.\n\nExclusion Criteria:\n\n* History of type 1 diabetes mellitus or a history of ketoacidosis.\n* History of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant.)\n* History of myocardial infarction, unstable angina, arterial revascularization, stroke, transient ischemic attack, or New York Heart Association (NYHA) functional class III-IV heart failure within 3 months of study start.\n* Mean value for triplicate screening sitting systolic blood pressure \\>160 mm Hg and/or diastolic blood pressure \\>90 mm Hg after at least a 5-minute seated rest at screening\n* Active, obstructive uropathy or indwelling urinary catheter.\n* History of malignancy \u22645 years prior to study start, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.\n* Routinely consumes \\>2 alcoholic drinks per day or \\>14 alcoholic drinks per week or engages in binge drinking.\n* Any clinically significant malabsorption condition.\n* Is on a weight-loss program or weight-loss medication or other medication associated with weight changes and is not weight stable prior to study start.\n* Has undergone bariatric surgery within the past 12 months or \\>12 months and is not weight stable prior to study start.\n* A known hypersensitivity or intolerance to any sodium glucose co-transporter (SGLT2) inhibitor.\n* On a previous clinical study with ertugliflozin.\n* Is taking blood pressure or lipid altering medications that have not been on a stable dose for at least 4 weeks prior to study start.\n* Current treatment for hyperthyroidism.\n* Male participants with a serum creatinine \\>=1.3 mg/dL (\\>=115 mol/L) or female participants with a serum creatinine \\>=1.2 mg/dL (\\>=106 mol/L) or participants with an estimated glomerular filtration rate (eGFR) \\<55 mL/min/1.73m\\^2 according to the 4-variable Modification of Diet in Renal Disease (MDRD) equation at screening.\n* An aspartate transaminase (AST) or alanine transaminase (ALT) \\>2X the upper limit of normal (ULN) range at screening, or a total bilirubin \\>1.5 X the ULN unless the participant has a history of Gilbert's.\n* On thyroid replacement therapy and has not been on a stable dose for at least 6 weeks prior to study start.\n* A medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease.\n* Has been treated with any of the following agents within 12 weeks of study start or during the pre-randomization period: Insulin of any type (except for short-term use during concomitant illness or other stress), other injectable anti-hyperglycemic agents (e.g., pramlintide, exenatide, liraglutide), another SGLT2 inhibitor, bromocriptine, colesevelam, rosiglitazone or pioglitazone, or any other AHA with the exception of the protocol-approved agents.\n* Is on or likely to require treatment \u226514 consecutive days or repeated courses of pharmacologic doses of corticosteroids.\n* Has undergone a surgical procedure within 6 weeks prior to study start or has planned major surgery during the study.\n* Pregnant or breast-feeding, or planning to conceive during the trial, including 14 days following the last dose of study medication.\n* Planning to undergo hormonal therapy in preparation for egg donation during the trial, including 14 days following the last dose of study medication.\n* Donated blood or blood products within 6 weeks of study start.\n* Has Human Immunodeficiency Virus (HIV).\n* Has blood dyscrasias or any disorders causing hemolysis or unstable red blood cells.\n* Has clinically important hematological disorders (such as aplastic anemia, myeloproliferative or myelodyplastic syndromes, thrombocytopenia.)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "34288547", "type": "DERIVED", "citation": "Xu H, O'Gorman MT, Nepal S, James LP, Ginman K, Pithavala YK. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1395-1404. doi: 10.1002/cpdd.1000. Epub 2021 Jul 20."}, {"pmid": "34213819", "type": "DERIVED", "citation": "Fediuk DJ, Sahasrabudhe V, Dawra VK, Zhou S, Sweeney K. Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations. Clin Pharmacol Drug Dev. 2021 Nov;10(11):1297-1306. doi: 10.1002/cpdd.970. Epub 2021 Jul 2."}, {"pmid": "30830724", "type": "DERIVED", "citation": "Ji L, Liu Y, Miao H, Xie Y, Yang M, Wang W, Mu Y, Yan P, Pan S, Lauring B, Liu S, Huyck S, Qiu Y, Terra SG. Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia. Diabetes Obes Metab. 2019 Jun;21(6):1474-1482. doi: 10.1111/dom.13681. Epub 2019 Apr 5."}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "In total, 1078 participants were screened, and 506 participants were randomized at 50 sites in China, Hong Kong, Republic of Korea, the Philippines, and Taiwan.", "groups": [{"id": "FG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "FG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "FG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "170"}, {"groupId": "FG001", "numSubjects": "169"}, {"groupId": "FG002", "numSubjects": "167"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "170"}, {"groupId": "FG001", "numSubjects": "169"}, {"groupId": "FG002", "numSubjects": "167"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "163"}, {"groupId": "FG001", "numSubjects": "160"}, {"groupId": "FG002", "numSubjects": "157"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "10"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "7"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "groups": [{"id": "BG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "BG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "BG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "56.1", "spread": "9.0"}, {"groupId": "BG001", "value": "56.3", "spread": "9.3"}, {"groupId": "BG002", "value": "56.9", "spread": "9.0"}, {"groupId": "BG003", "value": "56.5", "spread": "9.1"}]}]}]}, {"title": "Sex: Female, Male", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "75"}, {"groupId": "BG001", "value": "71"}, {"groupId": "BG002", "value": "79"}, {"groupId": "BG003", "value": "225"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "95"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "88"}, {"groupId": "BG003", "value": "281"}]}]}]}, {"title": "Race (NIH/OMB)", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Body Weight", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "71.4", "spread": "11.1"}, {"groupId": "BG001", "value": "69.5", "spread": "10.9"}, {"groupId": "BG002", "value": "70.1", "spread": "12.4"}, {"groupId": "BG003", "value": "70.3", "spread": "11.5"}]}]}]}, {"title": "Baseline Hemoglobin A1C (A1C)", "description": "Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "populationDescription": "The analysis population included all randomized participants who have received at least one dose of investigational product and had a baseline A1C measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage A1C", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "169"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "166"}, {"groupId": "BG003", "value": "504"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.14", "spread": "0.89"}, {"groupId": "BG001", "value": "8.09", "spread": "0.91"}, {"groupId": "BG002", "value": "8.13", "spread": "0.96"}, {"groupId": "BG003", "value": "8.12", "spread": "0.92"}]}]}]}, {"title": "Baseline Fasting Plasma Glucose (FPG)", "populationDescription": "The analysis population included all randomized participants who have received at least one dose of investigational product and had a baseline FPG measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "167"}, {"groupId": "BG001", "value": "168"}, {"groupId": "BG002", "value": "166"}, {"groupId": "BG003", "value": "501"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "170.1", "spread": "36.0"}, {"groupId": "BG001", "value": "167.3", "spread": "41.1"}, {"groupId": "BG002", "value": "165.8", "spread": "37.6"}, {"groupId": "BG003", "value": "167.8", "spread": "38.3"}]}]}]}, {"title": "Baseline estimated glomerular filtration rate (eGFR)", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73 m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "97.9", "spread": "19.2"}, {"groupId": "BG001", "value": "100.2", "spread": "19.8"}, {"groupId": "BG002", "value": "99.9", "spread": "20.2"}, {"groupId": "BG003", "value": "99.3", "spread": "19.7"}]}]}]}, {"title": "Country", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"title": "China", "measurements": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}, {"title": "Hong Kong", "measurements": [{"groupId": "BG000", "value": "10"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "7"}, {"groupId": "BG003", "value": "27"}]}, {"title": "Korea, Republic of", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "10"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "32"}]}, {"title": "Philippines", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "8"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "23"}]}, {"title": "Taiwan", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "18"}]}]}]}, {"title": "Anti-hyperglycemic Agent (AHA) Status at Screening (Metformin Alone OR Metformin + Another AHA)", "description": "Background AHA therapy at screening. Combination blood glucose lowering agents were counted twice, under each component of the combination.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Metformin alone", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "111"}, {"groupId": "BG001", "value": "121"}, {"groupId": "BG002", "value": "121"}, {"groupId": "BG003", "value": "353"}]}]}, {"title": "Metformin + Another AHA", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "170"}, {"groupId": "BG001", "value": "169"}, {"groupId": "BG002", "value": "167"}, {"groupId": "BG003", "value": "506"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "59"}, {"groupId": "BG001", "value": "48"}, {"groupId": "BG002", "value": "46"}, {"groupId": "BG003", "value": "153"}]}]}]}, {"title": "Gender (China Substudy)", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "66"}, {"groupId": "BG003", "value": "182"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "71"}, {"groupId": "BG001", "value": "84"}, {"groupId": "BG002", "value": "69"}, {"groupId": "BG003", "value": "224"}]}]}]}, {"title": "Age Continuous (China Substudy)", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "56.0", "spread": "9.0"}, {"groupId": "BG001", "value": "56.2", "spread": "9.4"}, {"groupId": "BG002", "value": "56.8", "spread": "8.6"}, {"groupId": "BG003", "value": "56.3", "spread": "9.0"}]}]}]}, {"title": "Body Weight (China Substudy)", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "71.4", "spread": "11.1"}, {"groupId": "BG001", "value": "70.2", "spread": "10.2"}, {"groupId": "BG002", "value": "70.6", "spread": "12.2"}, {"groupId": "BG003", "value": "70.7", "spread": "11.2"}]}]}]}, {"title": "Baseline A1C (China Substudy)", "description": "A1C is the ratio of glycated hemoglobin to total hemoglobin x 100.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and had a baseline A1C measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percentage A1C", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "134"}, {"groupId": "BG003", "value": "404"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.22", "spread": "0.94"}, {"groupId": "BG001", "value": "8.13", "spread": "0.96"}, {"groupId": "BG002", "value": "8.09", "spread": "0.98"}, {"groupId": "BG003", "value": "8.14", "spread": "0.96"}]}]}]}, {"title": "Baseline FPG (China Substudy)", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and had a baseline FPG measurement.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "135"}, {"groupId": "BG001", "value": "134"}, {"groupId": "BG002", "value": "134"}, {"groupId": "BG003", "value": "403"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "175.7", "spread": "36.2"}, {"groupId": "BG001", "value": "170.5", "spread": "43.0"}, {"groupId": "BG002", "value": "165.5", "spread": "37.9"}, {"groupId": "BG003", "value": "170.6", "spread": "39.3"}]}]}]}, {"title": "Baseline eGFR (China Substudy)", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mL/min/1.73 m^2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "99.8", "spread": "19.0"}, {"groupId": "BG001", "value": "102.7", "spread": "19.8"}, {"groupId": "BG002", "value": "100.8", "spread": "21.1"}, {"groupId": "BG003", "value": "101.1", "spread": "19.9"}]}]}]}, {"title": "Anti-AHA status at Screening (Metformin Alone OR Metformin + Another AHA) (China Substudy)", "description": "Background AHA therapy at screening. Combination blood glucose lowering agents were counted twice, under each component of the combination.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"title": "Metformin Alone", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "85"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "93"}, {"groupId": "BG003", "value": "270"}]}]}, {"title": "Metformin + Another AHA", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "136"}, {"groupId": "BG001", "value": "135"}, {"groupId": "BG002", "value": "135"}, {"groupId": "BG003", "value": "406"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "51"}, {"groupId": "BG001", "value": "43"}, {"groupId": "BG002", "value": "42"}, {"groupId": "BG003", "value": "136"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage A1C", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.00", "lowerLimit": "-1.12", "upperLimit": "-0.88"}, {"groupId": "OG001", "value": "-0.89", "lowerLimit": "-1.01", "upperLimit": "-0.77"}, {"groupId": "OG002", "value": "-0.20", "lowerLimit": "-0.33", "upperLimit": "-0.08"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "groupDescription": "The primary hypothesis of the study was the mean change from baseline in HbA1c for 15 mg ertugliflozin is greater than that for placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Constrained longitudinal data analysis (cLDA)", "pValue": "<0.001", "pValueComment": "cLDA model with fixed effects for treatment, time, anti-AHA status at Screening (metformin alone, metformin + another AHA), country (China, other), baseline eGFR (continuous) and the interaction of time by treatment.", "statisticalMethod": "cLDA", "statisticalComment": "Least squares means = LSM", "paramType": "Difference in the LSM vs. placebo", "paramValue": "-0.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.85", "ciUpperLimit": "-0.52"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "The primary hypothesis of the study was the mean change from baseline in HbA1c for 5 mg ertugliflozin is greater than that for placebo.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-AHA status at Screening (metformin alone, metformin + another AHA), country (China, other), baseline eGFR (continuous) and the interaction of time by treatment.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-0.80", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.97", "ciUpperLimit": "-0.63"}]}, {"type": "PRIMARY", "title": "Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percentage A1C", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.01", "lowerLimit": "-1.14", "upperLimit": "-0.87"}, {"groupId": "OG001", "value": "-0.92", "lowerLimit": "-1.05", "upperLimit": "-0.79"}, {"groupId": "OG002", "value": "-0.24", "lowerLimit": "-0.38", "upperLimit": "-0.10"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "cLDA model with fixed effects for treatment, time, anti-AHA status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment.", "statisticalMethod": "cLDA", "paramType": "Difference in the LSM vs. placebo", "paramValue": "-0.68", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.86", "ciUpperLimit": "-0.50"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-AHA status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-0.76", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.95", "ciUpperLimit": "-0.58"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 28 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "56.5"}, {"groupId": "OG001", "value": "53.3"}, {"groupId": "OG002", "value": "59.3"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in % vs. Placebo", "paramValue": "-6.0", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.5", "ciUpperLimit": "4.6", "otherAnalysisDescription": "Miettinen-Nurminen method"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in % vs. Placebo", "paramValue": "-2.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-13.3", "ciUpperLimit": "7.7", "otherAnalysisDescription": "Miettinen-Nurminen method"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product .", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Up to 28 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "54.4"}, {"groupId": "OG001", "value": "50.4"}, {"groupId": "OG002", "value": "59.3"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in % vs. Placebo", "paramValue": "-8.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-20.5", "ciUpperLimit": "3.0", "otherAnalysisDescription": "Miettinen-Nurminen method"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "paramType": "Difference in % vs. Placebo", "paramValue": "-4.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-16.5", "ciUpperLimit": "6.9", "otherAnalysisDescription": "Miettinen-Nurminen method"}]}, {"type": "PRIMARY", "title": "Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to 26 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2"}, {"groupId": "OG001", "value": "0.6"}, {"groupId": "OG002", "value": "1.8"}]}]}]}, {"type": "PRIMARY", "title": "Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Up to 26 weeks", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.7"}, {"groupId": "OG001", "value": "0.7"}, {"groupId": "OG002", "value": "2.2"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-37.09", "lowerLimit": "-41.73", "upperLimit": "-32.45"}, {"groupId": "OG001", "value": "-34.47", "lowerLimit": "-39.15", "upperLimit": "-29.79"}, {"groupId": "OG002", "value": "-6.69", "lowerLimit": "-11.57", "upperLimit": "-1.82"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "-27.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-33.85", "ciUpperLimit": "-21.70"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "-30.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-36.45", "ciUpperLimit": "-24.35"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-39.01", "lowerLimit": "-43.87", "upperLimit": "-34.15"}, {"groupId": "OG001", "value": "-36.67", "lowerLimit": "-41.64", "upperLimit": "-31.71"}, {"groupId": "OG002", "value": "-10.46", "lowerLimit": "-15.61", "upperLimit": "-5.31"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "-26.21", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-32.41", "ciUpperLimit": "-20.01"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "-28.55", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-34.67", "ciUpperLimit": "-22.43"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)", "description": "The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants and who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.95", "lowerLimit": "-3.29", "upperLimit": "-2.60"}, {"groupId": "OG001", "value": "-3.18", "lowerLimit": "-3.52", "upperLimit": "-2.83"}, {"groupId": "OG002", "value": "-1.17", "lowerLimit": "-1.54", "upperLimit": "-0.81"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "-2.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.51", "ciUpperLimit": "-1.50"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-1.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.28", "ciUpperLimit": "-1.28"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post-baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-3.11", "lowerLimit": "-3.50", "upperLimit": "-2.72"}, {"groupId": "OG001", "value": "-3.38", "lowerLimit": "-3.78", "upperLimit": "-2.98"}, {"groupId": "OG002", "value": "-1.33", "lowerLimit": "-1.75", "upperLimit": "-0.91"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "-2.05", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.63", "ciUpperLimit": "-1.21"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-1.79", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.36", "ciUpperLimit": "-1.21"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "38.2"}, {"groupId": "OG001", "value": "40.8"}, {"groupId": "OG002", "value": "16.2"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "4.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.49", "ciUpperLimit": "8.35"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "4.59", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.52", "ciUpperLimit": "8.36"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "35.3"}, {"groupId": "OG001", "value": "42.2"}, {"groupId": "OG002", "value": "18.5"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "4.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.32", "ciUpperLimit": "8.68"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "3.47", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.77", "ciUpperLimit": "6.80"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.09", "lowerLimit": "-6.78", "upperLimit": "-3.40"}, {"groupId": "OG001", "value": "-3.87", "lowerLimit": "-5.58", "upperLimit": "-2.16"}, {"groupId": "OG002", "value": "0.22", "lowerLimit": "-1.58", "upperLimit": "2.01"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-4.09", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.48", "ciUpperLimit": "-1.69"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "<0.001", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-5.30", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.68", "ciUpperLimit": "-2.92"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-5.64", "lowerLimit": "-7.53", "upperLimit": "-3.75"}, {"groupId": "OG001", "value": "-4.19", "lowerLimit": "-6.14", "upperLimit": "-2.25"}, {"groupId": "OG002", "value": "-1.56", "lowerLimit": "-3.61", "upperLimit": "0.49"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "0.058", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-2.64", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.36", "ciUpperLimit": "0.09"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "0.003", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-4.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.78", "ciUpperLimit": "-1.39"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)", "description": "This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.38", "lowerLimit": "-3.51", "upperLimit": "-1.25"}, {"groupId": "OG001", "value": "-2.36", "lowerLimit": "-3.50", "upperLimit": "-1.22"}, {"groupId": "OG002", "value": "-0.96", "lowerLimit": "-2.16", "upperLimit": "0.24"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "0.086", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-1.40", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.00", "ciUpperLimit": "0.20"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "0.081", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-1.42", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.01", "ciUpperLimit": "0.17"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)", "description": "This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.82", "lowerLimit": "-4.11", "upperLimit": "-1.54"}, {"groupId": "OG001", "value": "-2.77", "lowerLimit": "-4.09", "upperLimit": "-1.45"}, {"groupId": "OG002", "value": "-1.82", "lowerLimit": "-3.21", "upperLimit": "-0.43"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "0.315", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-0.95", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.80", "ciUpperLimit": "0.90"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "cLDA model with fixed effects for treatment, time, anti-hyperglycemic medication status at Screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and the interaction of time by treatment. Time was treated as a categorical variable.", "pValue": "0.282", "statisticalMethod": "cLDA", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "-1.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.83", "ciUpperLimit": "0.83"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.7"}, {"groupId": "OG001", "value": "15.4"}, {"groupId": "OG002", "value": "2.4"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "0.001", "pValueComment": "Nominal p-values were provided.", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "8.90", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.46", "ciUpperLimit": "32.22"}, {"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "pValueComment": "Nominal p-values were provided.", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "10.69", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.95", "ciUpperLimit": "38.71"}]}, {"type": "SECONDARY", "title": "Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)", "description": "A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one assessment of the respective endpoint at baseline or post baseline up to Week 26.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "14.7"}, {"groupId": "OG001", "value": "17.0"}, {"groupId": "OG002", "value": "3.0"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted Odds Ratio based on a logistic regression model fitted with fixed effects for treatment anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), Country (China, other), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "pValueComment": "Nominal p-values were provided.", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "8.34", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.52", "ciUpperLimit": "27.60"}, {"groupIds": ["OG000"], "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Adjusted odds ratio based on a logistic regression model fitted with fixed effects for treatment, anti-hyperglycemic medication status at screening (metformin alone, metformin + another AHA), baseline eGFR (continuous) and baseline A1C (continuous). Missing data imputed using the cLDA model fitted with fixed effects as in the primary analysis.", "pValue": "<0.001", "pValueComment": "Nominal p-values were provided.", "statisticalMethod": "Logistic regression model", "paramType": "Adjusted Odds Ratio relative to placebo", "paramValue": "8.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "2.44", "ciUpperLimit": "28.11"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "167"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.2"}, {"groupId": "OG001", "value": "0.6"}, {"groupId": "OG002", "value": "9.6"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Miettinen & Nurminen method", "statisticalComment": "Miettinen \\& Nurminen method stratified by country ('China' or 'other') for the overall population.", "paramType": "Difference in % (Ert. 15 mg. - placebo)", "paramValue": "-9.0", "ciPctValue": "95", "ciLowerLimit": "-14.5", "ciUpperLimit": "-5.0"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Miettinen & Nurminen method", "statisticalComment": "Miettinen \\& Nurminen method stratified by country ('China' or 'other') for the overall population.", "paramType": "Difference in % (Ert. 5 mg. - placebo)", "paramValue": "-8.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-14.0", "ciUpperLimit": "-4.4"}]}, {"type": "SECONDARY", "title": "Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 26", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.0"}, {"groupId": "OG001", "value": "0.7"}, {"groupId": "OG002", "value": "9.6"}]}]}], "analyses": [{"groupIds": ["OG001", "OG002"], "nonInferiorityType": "OTHER", "pValue": "0.001", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Difference in % (Ert. 15 mg. - placebo)", "paramValue": "-8.9", "ciPctValue": "95", "ciLowerLimit": "-15.1", "ciUpperLimit": "-4.2"}, {"groupIds": ["OG000", "OG002"], "nonInferiorityType": "OTHER", "pValue": "<0.001", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Difference in % (Ert. 5 mg. - placebo)", "paramValue": "-9.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-15.8", "ciUpperLimit": "-5.7"}]}, {"type": "SECONDARY", "title": "Time to Glycemic Rescue Therapy", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product who received glycemic rescue through Week 26.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Days", "timeFrame": "Up to 183 days", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "16"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "NA", "lowerLimit": "41", "upperLimit": "85", "comment": "The median is not estimable due to the low number of participants rescued."}, {"groupId": "OG001", "value": "NA", "lowerLimit": "149", "upperLimit": "149", "comment": "The median is not estimable due to the low number of participants rescued."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "22", "upperLimit": "183", "comment": "The median is not estimable due to the low number of participants rescued."}]}]}]}, {"type": "SECONDARY", "title": "Time to Glycemic Rescue Therapy (China Subpopulation)", "description": "Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who received glycemic rescue through Week 26. No participants in the Ertugliflozin 5 mg group were rescued.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "Days", "timeFrame": "Up to 149 days", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG001", "value": "NA", "lowerLimit": "149", "upperLimit": "149", "comment": "The median is not estimable due to the low number of participants rescued."}, {"groupId": "OG002", "value": "NA", "lowerLimit": "22", "upperLimit": "145", "comment": "The median is not estimable due to the low number of participants rescued."}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 6: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.17", "spread": "18.39"}, {"groupId": "OG001", "value": "24.59", "spread": "43.84"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 12: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "8.18", "spread": "15.25"}, {"groupId": "OG001", "value": "27.11", "spread": "66.02"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 12: 60 min. Post-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "91.49", "spread": "50.61"}, {"groupId": "OG001", "value": "277.60", "spread": "130.66"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 18: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.59", "spread": "12.53"}, {"groupId": "OG001", "value": "17.54", "spread": "24.62"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 18: 60 min. Post-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "91.40", "spread": "44.77"}, {"groupId": "OG001", "value": "274.23", "spread": "146.14"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 26: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "170"}, {"groupId": "OG001", "value": "169"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.34", "spread": "14.18"}, {"groupId": "OG001", "value": "26.66", "spread": "62.17"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 6: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.88", "spread": "14.88"}, {"groupId": "OG001", "value": "22.29", "spread": "42.81"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 12: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "136"}, {"groupId": "OG001", "value": "135"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.40", "spread": "12.21"}, {"groupId": "OG001", "value": "23.84", "spread": "52.64"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 12: 60 min. Post-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "131"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "97.36", "spread": "48.98"}, {"groupId": "OG001", "value": "294.49", "spread": "124.73"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 18: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6.30", "spread": "11.50"}, {"groupId": "OG001", "value": "17.07", "spread": "27.06"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 18: 60 min. Post-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "125"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "94.82", "spread": "41.40"}, {"groupId": "OG001", "value": "285.28", "spread": "141.59"}]}]}]}, {"type": "SECONDARY", "title": "Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)", "description": "No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.", "populationDescription": "The analysis population included all randomized participants in China who received at least one dose of investigational product and who had at least one plasma concentration value above the lower limit of quantification. No ertugliflozin plasma concentrations were determined for participants receiving placebo.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/mL", "timeFrame": "Week 26: Pre-Dose", "groups": [{"id": "OG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}, {"id": "OG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "127"}, {"groupId": "OG001", "value": "118"}, {"groupId": "OG002", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.26", "spread": "14.09"}, {"groupId": "OG001", "value": "24.91", "spread": "57.95"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to 28 weeks", "description": "The analysis population included all randomized and treated participants.", "eventGroups": [{"id": "EG000", "title": "Ertugliflozin 5 mg", "description": "Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.", "deathsNumAffected": 0, "deathsNumAtRisk": 170, "seriousNumAffected": 9, "seriousNumAtRisk": 170, "otherNumAffected": 22, "otherNumAtRisk": 170}, {"id": "EG001", "title": "Ertugliflozin 15 mg", "description": "Ertugliflozin 15 mg administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.", "deathsNumAffected": 0, "deathsNumAtRisk": 169, "seriousNumAffected": 10, "seriousNumAtRisk": 169, "otherNumAffected": 31, "otherNumAtRisk": 169}, {"id": "EG002", "title": "Placebo", "description": "Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.", "deathsNumAffected": 0, "deathsNumAtRisk": 167, "seriousNumAffected": 2, "seriousNumAtRisk": 167, "otherNumAffected": 44, "otherNumAtRisk": 167}], "seriousEvents": [{"term": "Iron deficiency anaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Microvascular coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Vertigo positional", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Cataract", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Dacryostenosis acquired", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Intestinal polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Cholecystitis chronic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Craniocerebral injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Limb injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Patella fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Diabetes mellitus inadequate control", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}]}, {"term": "Intervertebral disc protrusion", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Adenocarcinoma gastric", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Clear cell renal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Cerebellar infarction", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Cubital tunnel syndrome", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 167}]}, {"term": "Hydronephrosis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 167}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 13, "numAffected": 9, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 11, "numAffected": 9, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 13, "numAffected": 11, "numAtRisk": 167}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 16, "numAffected": 14, "numAtRisk": 167}]}, {"term": "Hyperuricaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 5, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 21, "numAffected": 20, "numAtRisk": 167}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 6, "numAtRisk": 170}, {"groupId": "EG001", "numEvents": 10, "numAffected": 9, "numAtRisk": 169}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 167}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Investigator will provide manuscripts, abstracts, or the full text of any other intended disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to the sponsor at least 30 days before they are submitted for publication or otherwise disclosed. If any patent action is required to protect intellectual property rights, Investigator agrees to delay the disclosure for a period not to exceed an additional 60 days."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2014-03-09", "uploadDate": "2018-11-13T16:46", "filename": "Prot_SAP_000.pdf", "size": 8191203}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["China", "Hong Kong", "Korea, Republic of", "Philippines", "Taiwan"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000570288", "term": "Ertugliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}, {"id": "D000077203", "term": "Sodium-Glucose Transporter 2 Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M263808", "name": "Ertugliflozin", "asFound": "True", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}, {"id": "M1691", "name": "Sodium-Glucose Transporter 2 Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}]}}, "hasResults": true}